New Registration Provisions Will Strengthen Chinese Oversight Of Pharma Industry
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State Food and Drug Administration revised its drug registration provisions July 12, improving supervision and tightening approval standards in the wake of widespread concern related to drug safety
You may also be interested in...
Simcere's Endu Becomes First Drug To Complete Phase IV Trials Under New Drug Registration Regs
SHANGHAI- Simcere Pharmaceutical Group, a leading Chinese pharmaceutical and biotech firm, announced March 22 that its biopharmaceutical Endu (recombinant human endostatin injection) for non-small cell lung cancer (NSCLC) has completed Phase IV clinical trials and became the first drug to pass re-registration procedures outlined by China's State FDA
Simcere's Endu Becomes First Drug To Complete Phase IV Trials Under New Drug Registration Regs
SHANGHAI- Simcere Pharmaceutical Group, a leading Chinese pharmaceutical and biotech firm, announced March 22 that its biopharmaceutical Endu (recombinant human endostatin injection) for non-small cell lung cancer (NSCLC) has completed Phase IV clinical trials and became the first drug to pass re-registration procedures outlined by China's State FDA
More Investment In China’s Health Care System Unveiled During NPC; Is It Time To Ask Who Will Benefit First And Most?
SHANGHAI - With the world economy in a downturn, the annual session of China's National People's Congress, one of the most important meetings in the country, is being held in Beijing